|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-4-28
|
|
pubmed:abstractText |
The risk of infection with Pneumocystis jirovecii pneumonia (PCP) in patients undergoing chemotherapy is closely related to the intensity of corticosteroid exposure. PCP is uncommon with classical (3-weekly) R-CHOP, but the risk may be higher with biweekly R-CHOP (R-CHOP-14) due to the increased frequency of prednisolone pulses. Among 47 consecutive patients treated with R-CHOP-14 at our institution, five (11%) developed microbiologically proven PCP, with a further two (4%) having classical clinical and radiological features of PCP, but without microbiological confirmation. None of these patients were HIV-positive or had additional risk factors for PCP. Our experience suggests that PCP prophylaxis should be considered in institutions using R-CHOP-14 for the treatment of patients with aggressive lymphomas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1029-2403
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
797-801
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20367135-Adult,
pubmed-meshheading:20367135-Aged,
pubmed-meshheading:20367135-Aged, 80 and over,
pubmed-meshheading:20367135-Antibodies, Monoclonal,
pubmed-meshheading:20367135-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20367135-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20367135-Cohort Studies,
pubmed-meshheading:20367135-Cyclophosphamide,
pubmed-meshheading:20367135-Doxorubicin,
pubmed-meshheading:20367135-Female,
pubmed-meshheading:20367135-Humans,
pubmed-meshheading:20367135-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:20367135-Male,
pubmed-meshheading:20367135-Middle Aged,
pubmed-meshheading:20367135-Neoplasm Recurrence, Local,
pubmed-meshheading:20367135-Pneumocystis jirovecii,
pubmed-meshheading:20367135-Pneumonia, Pneumocystis,
pubmed-meshheading:20367135-Prednisone,
pubmed-meshheading:20367135-Retrospective Studies,
pubmed-meshheading:20367135-Survival Rate,
pubmed-meshheading:20367135-Treatment Outcome,
pubmed-meshheading:20367135-Vincristine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
|
|
pubmed:affiliation |
Hematology Department, St Vincent's Hospital, Melbourne, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
